Latin name
Cozaar ®
ATC:
>> C09CA01 Losartan
Pharmacological Group
>> Receptor antagonists of angiotensin II (AT1-subtype)
Nosological classification (ICD-10)
>> I10-I15 Diseases characterized by high blood pressure
>> I50 Heart failure
The composition and the form
1 tablet contains losartan potassium 12.5 or 50 mg in the contour of cellular packing 21 or 14 pieces., In box 2 and 1 pack respectively.
Pharmacological action
Mode of action – hypotensive. Blocks angiotensin II (type AT1) reduces OPSS, reduces afterload, reduces systemic blood pressure and the pressure in the lesser circulation.
Pharmacokinetics
Well absorbed. Be distributed relatively evenly. Metabolized to form the active derivative.
Pharmacodynamics
Maximum antihypertensive effect is achieved within 3-6 weeks of treatment.
Indications
Arterial hypertension, heart failure (including when treatment with ACE inhibitors is no longer appropriate for the patient.
Contraindications
Hypersensitivity, children’s age.
Application of pregnancy and breastfeeding
When the reception immediately terminate pregnancy (may cause developmental defects or fetal death, especially in the II-III trimester). Nursing mothers should stop breastfeeding.
Side effects
Dizziness, hypotension (dose-related), hyperkalemia (1.5% of patients).
Interaction
Compatible with other antihypertensive agents. Against the background of diuretics (high doses) increases the risk of excessive hypotension in patients with dehydration.
Overdose
The most likely manifestation – hypotension and tachycardia (possible vagal bradycardia). Treatment of symptomatic – no Kozaar nor its active metabolite are not displayed hemodialysis.
Dosing and Administration
Inside, regardless of the meal, once. Usually – 50 mg / day. In some cases, to achieve greater effect, increase the dose to 100 mg. Patients with dehydration may make an initial dose of 25 mg / day. For patients with heart failure the initial dose may reach 12.5 mg 1 time per day.
Precautions
Patients with a history of liver disease should be prescribed lower doses (plasma concentration significantly increased for violations of its functions, especially with cirrhosis).
Expiration
3 years
Storage
List B.: In the dark place at a temperature not above 25 ° C.
Date update
2001-07-31
Latin name
Cozaar ®
ATC:
>> C09CA01 Losartan
Pharmacological Group
>> Receptor antagonists of angiotensin II (AT1-subtype)
Nosological classification (ICD-10)
>> I10-I15 Diseases characterized by high blood pressure
>> I50 Heart failure
The composition and the form
1 tablet contains losartan potassium 12.5 or 50 mg in the contour of cellular packing 21 or 14 pieces., In box 2 and 1 pack respectively.
Pharmacological action
Mode of action – hypotensive. Blocks angiotensin II (type AT1) reduces OPSS, reduces afterload, reduces systemic blood pressure and the pressure in the lesser circulation.
Pharmacokinetics
Well absorbed. Be distributed relatively evenly. Metabolized to form the active derivative.
Pharmacodynamics
Maximum antihypertensive effect is achieved within 3-6 weeks of treatment.
Indications
Arterial hypertension, heart failure (including when treatment with ACE inhibitors is no longer appropriate for the patient.
Contraindications
Hypersensitivity, children’s age.
Application of pregnancy and breastfeeding
When the reception immediately terminate pregnancy (may cause developmental defects or fetal death, especially in the II-III trimester). Nursing mothers should stop breastfeeding.
Side effects
Dizziness, hypotension (dose-related), hyperkalemia (1.5% of patients).
Interaction
Compatible with other antihypertensive agents. Against the background of diuretics (high doses) increases the risk of excessive hypotension in patients with dehydration.
Overdose
The most likely manifestation – hypotension and tachycardia (possible vagal bradycardia). Treatment of symptomatic – no Kozaar nor its active metabolite are not displayed hemodialysis.
Dosing and Administration
Inside, regardless of the meal, once. Usually – 50 mg / day. In some cases, to achieve greater effect, increase the dose to 100 mg. Patients with dehydration may make an initial dose of 25 mg / day. For patients with heart failure the initial dose may reach 12.5 mg 1 time per day.
Precautions
Patients with a history of liver disease should be prescribed lower doses (plasma concentration significantly increased for violations of its functions, especially with cirrhosis).
Expiration
3 years
Storage
List B.: In the dark place at a temperature not above 25 ° C.
Date update
2001-07-31
